Moderna Says mRNA Flu Vaccine Sailed Through Trial, Beating Standard Shot (arstechnica.com)
(Saturday July 05, 2025 @05:34PM (msmash)
from the encouraging-feedback dept.)
Moderna's mRNA-based seasonal flu vaccine [1]proved 27% more effective at preventing influenza infections than standard flu shots in a Phase 3 trial involving nearly 41,000 people aged 50 and above, the firm said this week.
The company announced that mRNA-1010 had an overall vaccine efficacy that was 26.6% higher than conventional shots, rising to 27.4% higher in participants aged 65 and older during the six-month study period. The 2024-2025 flu season hospitalized an estimated 770,000 Americans, according to the Centers for Disease Control and Prevention.
[1] https://arstechnica.com/health/2025/07/moderna-says-its-mrna-seasonal-flu-shot-is-27-better-than-current-vaccine/
The company announced that mRNA-1010 had an overall vaccine efficacy that was 26.6% higher than conventional shots, rising to 27.4% higher in participants aged 65 and older during the six-month study period. The 2024-2025 flu season hospitalized an estimated 770,000 Americans, according to the Centers for Disease Control and Prevention.
[1] https://arstechnica.com/health/2025/07/moderna-says-its-mrna-seasonal-flu-shot-is-27-better-than-current-vaccine/